GLOW Peptide (Klow): A Compounded Tripeptide-Antioxidant Blend for Skin Rejuvenation

This content is provided by Superpower Health for educational and informational purposes only. GLOW (Klow) and similar branded skin peptide blends are not FDA-approved for any indication. The formulation discussed here is a compounded preparation; exact ingredients vary by pharmacy. This page is not a substitute for medical advice. Always consult a qualified healthcare provider before using any injectable cosmetic compound.

Search for "glow peptide" or "klow peptide" and the results split into two camps: compounding pharmacy marketing that emphasizes luminous skin and rapid results, and clinical skepticism questioning whether any of this belongs in a syringe at all. Neither extreme gives you a useful picture.

This guide covers what GLOW is, what each ingredient in the standard formulation has been studied for, where the evidence is credible, where it runs thin, and what a baseline assessment should include before anyone starts an injectable cosmetic regimen.

Key Takeaways

• What it is: A compounded injectable blend, typically GHK-Cu + glutathione + ascorbic acid, marketed for skin rejuvenation under brand names including GLOW and Klow.
• FDA status: Not FDA-approved for any indication. Each ingredient exists in other FDA-approved contexts; the blend as an injectable cosmetic does not.
• Evidence base: Individual ingredients have peer-reviewed research supporting skin-relevant mechanisms; no RCT exists for the blend itself or for the injectable route specifically for skin outcomes.
• Access: Prescription only, dispensed by licensed 503A compounding pharmacies with a patient-specific prescription from a licensed provider.
• Testing first: Baseline liver function, renal function, CBC, and copper status are relevant safety checkpoints before injectable compounded preparations.

What Is the GLOW Peptide (Klow)?

GLOW (marketed under names including Klow and various pharmacy-specific brand designations) is a compounded injectable preparation that combines peptide and antioxidant ingredients intended to support skin appearance, texture, and pigmentation. It is not a single molecule with a defined pharmacological identity. It is a formulated blend, and the exact composition, concentration, and delivery medium vary by compounding pharmacy. The standard formulation most commonly cited in clinical and consumer contexts contains three active ingredients: GHK-Cu (glycyl-L-histidyl-L-lysine copper complex, also written as copper tripeptide-1), glutathione (reduced L-glutathione, GSH), and ascorbic acid (vitamin C).

Each of these ingredients has an independent research history in dermatology and biochemistry. GHK-Cu has been studied for decades in the context of wound healing and dermal remodeling. Glutathione has been evaluated in clinical trials as a skin-lightening and antioxidant agent. Ascorbic acid is one of the most extensively characterized skin-active compounds in medicine, with a well-established role as a collagen synthesis cofactor and photoprotective antioxidant. Their combination in an injectable format marketed for cosmetic outcomes is a relatively recent phenomenon driven by compounding pharmacy channels, not by FDA-approved drug development.

The name "peptide" in GLOW's marketing refers specifically to GHK-Cu, which is a tripeptide (three amino acids: glycine, histidine, lysine) complexed with copper. Glutathione is a tripeptide as well, by strict chemical definition, though it is more commonly categorized in clinical contexts as an antioxidant rather than a signaling peptide. Ascorbic acid is not a peptide at all.

What Each Ingredient Does: The Biology

GHK-Cu (copper tripeptide-1)

GHK-Cu has one of the longer research pedigrees of any compound in this category. The tripeptide glycyl-L-histidyl-L-lysine was first isolated from human serum by Pickart and Thayer, whose 1973 paper in Biochemical and Biophysical Research Communications documented that the synthetic tripeptide prolongs survival of normal liver cells at nanomolar concentrations, establishing the foundational observation that small peptide fragments in circulation have tissue-maintenance functions. Pickart and Thaler characterized the structure-activity relationship of the GHK plasma tripeptide in a 1979 FEBS Letters paper, initiating decades of research before its combination with copper became the focus of skin applications.

The primary mechanism relevant to skin is collagen remodeling. A 2008 review by Pickart in the Journal of Biomaterials Science summarized GHK-Cu's documented roles in wound healing, dermal remodeling, and skin elasticity, finding that the complex modulates both synthesis and degradation pathways in the extracellular matrix. A more recent 2018 review by Pickart and Margolina in the International Journal of Molecular Sciences documented GHK-Cu's influence on the expression of more than 4,000 human genes related to tissue remodeling, antioxidant defense, and anti-inflammatory signaling — an observation that positions GHK-Cu as a broad-spectrum tissue-regulatory signal rather than a compound with a single mechanism. The gene-regulatory reach has been demonstrated in disease-relevant tissue as well: a 2012 preclinical study by Campbell and colleagues in Genome Medicine profiled 64 lung tissue regions from 8 COPD patients and used connectivity-map analysis to identify GHK as capable of reversing the emphysema-associated gene-expression signature; in ex vivo distal-lung fibroblasts from smokers and COPD donors, GHK reorganized the actin cytoskeleton, elevated integrin β1, and restored collagen-I contraction and remodeling capacity to levels comparable with TGF-β treatment. This is preclinical gene-expression and cell-biology evidence in human-derived tissue, not a demonstration of clinical benefit in patients, but it extends the mechanistic case for GHK-Cu's tissue-remodeling activity beyond wound surfaces.

At the structural level, a 2023 in vitro study by Dymek and colleagues published in Pharmaceutics found that liposomal GHK-Cu reduces elastin degeneration and supports dermal structural integrity in cell culture models. A separate 2023 ex vivo human skin study by Jiang and colleagues in the Journal of Cosmetic Dermatology found that GHK-Cu combined with hyaluronic acid synergistically upregulates collagen IV expression in human dermal tissue, providing mechanism-level support for collagen-stimulation effects at the extracellular matrix level.

The translational challenge with GHK-Cu is delivery. A 2025 review by Mortazavi and Mohammadi Vadoud in BioImpacts flagged skin permeability as the main barrier to translating topical GHK-Cu data into clinical outcomes — the compound does not reliably penetrate intact skin at concentrations used in topical products. This barrier is part of the rationale for injectable delivery, though injectable GHK-Cu for cosmetic outcomes has no published RCT data of its own. A randomized controlled trial by Miller, Wagner, and colleagues published in the Archives of Facial Plastic Surgery in 2006 evaluated topical copper tripeptide complex on CO2 laser-resurfaced skin in 13 patients and found no statistically significant differences between groups for resolution of erythema, wrinkles, or overall skin quality on objective assessment, although subjective patient-reported skin quality favored the GHK-Cu side (p = 0.04). The very small sample limits the strength of the finding, but the objective-outcome null result raises questions about the magnitude of clinical effect even when the skin's barrier is compromised. The gap between mechanistic plausibility and demonstrated clinical outcomes is real and should inform expectations.

Glutathione

Glutathione (GSH, gamma-glutamylcysteinylglycine) is the body's most abundant endogenous antioxidant, present in virtually all mammalian cells. Its relevance to skin appearance operates through two primary mechanisms: melanogenesis inhibition and oxidative stress reduction. Villarama and Maibach's foundational 2005 overview in the International Journal of Cosmetic Science established the framework: glutathione attenuates skin pigmentation through tyrosinase inactivation and free-radical quenching, two pathways central to melanin synthesis.

The molecular mechanism has since been elaborated. A 2014 study by Nakajima, Nagata, and colleagues published in Archives of Dermatological Research showed that reduced glutathione disrupts intracellular trafficking of tyrosinase to melanosomes, the rate-limiting enzyme in melanin synthesis, attenuating melanization at the cellular level. A 2021 mechanistic paper by Lu and Tonissen in Bioscience Reports detailed how the thioredoxin and glutathione systems cooperatively regulate melanogenesis pathways at the redox level, providing biochemical depth to the skin-lightening observation.

In clinical trials, the evidence is most robust for oral glutathione. An earlier double-blind RCT by Arjinpathana and Asawanonda published in the Journal of Dermatological Treatment in 2012 (n=60, oral GSH 500 mg/day for 4 weeks) found that oral glutathione produced a modest skin-lightening effect in sun-exposed areas versus placebo, establishing the foundational clinical signal for the oral route. Weschawalit and colleagues subsequently published a randomized controlled trial in Clinical, Cosmetic and Investigational Dermatology in 2017 (N=60 women, 12 weeks) finding that oral glutathione at 250 mg/day produced favorable effects on skin elasticity, wrinkle reduction, and UV spot reduction compared with placebo. A 2022 double-blind, benchmark- and placebo-controlled RCT by Duperray, Sergheraert, and colleagues in the Journal of Cosmetic Dermatology (n=124 Asian women, 12 weeks) found that oral L-cystine plus reduced L-glutathione significantly lightened skin and reduced facial dark spot size at both 6 and 12 weeks versus placebo. A 2021 double-blind RCT by Wahab and colleagues in the International Journal of Dermatology (n=46, 8 weeks, colorimetric melanin index endpoint) found that combined topical plus oral glutathione produced a significantly lower melanin index and L* score versus placebo, with the combination outperforming monotherapy. A 2022 clinical review by Sharma and Sharma in Clinical, Cosmetic and Investigational Dermatology examined oral-mucosa (sublingual and buccal) glutathione absorption and its effect on skin pigmentation, noting that non-injected delivery routes can achieve meaningful bioavailability when first-pass metabolism is bypassed.

Bioavailability is the central complication for injectable use. A 2016 in vitro study by Chung and colleagues in the International Journal of Molecular Sciences found that plain reduced glutathione does not whiten skin effectively due to poor cellular uptake, while a modified ester derivative performed better — a finding that raises formulation-specific questions about which glutathione form is in a given GLOW preparation and whether it delivers bioactive intracellular concentrations. A 2019 systematic review by Dilokthornsakul and colleagues in the Journal of Cosmetic Dermatology searched five databases through October 2017 and included four clinical studies (three placebo-controlled RCTs and one single-arm trial) evaluating oral glutathione 250-500 mg/day and topical 2% oxidized glutathione, concluding that evidence for skin-whitening effects remained inconclusive due to inconsistent findings across trials and the limited bioavailability of oral GSH — with no significant effect observed in sun-protected skin areas. A widely cited 2016 review by Sonthalia and Daulatabad in the Indian Journal of Dermatology, Venereology and Leprology addressed the facts, myths, and controversies around glutathione as a skin-whitening agent, cautioning against the promotional claims that routinely outrun the underlying clinical data. A 2025 systematic review by Sarkar, Yadav, and colleagues in the International Journal of Dermatology analyzed evidence across topical (0.1-2%), oral (250-500 mg/day), and intravenous routes — including five oral RCTs and additional topical and IV studies — and characterized topical and oral glutathione as moderately effective (with topical 0.5% superior to lower concentrations and combined topical-plus-oral outperforming monotherapy) while explicitly flagging intravenous glutathione as contraindicated due to lack of efficacy and adverse side effects, citing a single placebo-controlled IV study in which 37.5% (6/16) of the treatment group versus 18.7% (3/16) of the placebo group achieved the endpoint (p = 0.054, not statistically significant). A 2025 narrative review by Alzahrani and Alotaibi in Cureus reached a similar safety conclusion, noting that long-term safety and optimal dosing of glutathione supplementation for skin lightening require larger trials before firm recommendations can be made. This contraindication for IV use, combined with the limited long-term safety data, is clinically significant for any injectable glutathione preparation.

Ascorbic acid (vitamin C)

Ascorbic acid is the most extensively studied of the three GLOW ingredients for skin applications. It functions as an obligatory cofactor for prolyl and lysyl hydroxylase, the enzymes that hydroxylate proline and lysine residues during collagen biosynthesis — a role that is biochemically non-negotiable, meaning collagen cannot be properly synthesized without it. A comprehensive 2017 review by Pullar and Carr in Nutrients documents vitamin C's established role as a collagen synthesis cofactor, antioxidant, and UV-protective agent in skin tissue.

Controlled clinical and biopsy-level evidence for topical ascorbic acid is among the strongest in cosmetic dermatology. A 2001 RCT by Nusgens and colleagues published in the Journal of Investigative Dermatology (N=33) used punch biopsy to demonstrate that topical vitamin C significantly increases mRNA levels of collagen I, collagen III, and tissue inhibitor of metalloproteinase-1 (TIMP-1) in the human dermis — direct molecular evidence of collagen gene upregulation at the tissue level. A 2003 double-blind placebo-controlled trial by Humbert and colleagues in Experimental Dermatology applied 5% topical ascorbic acid cream versus vehicle to the low-neck and arms of healthy women with photoaged skin for 6 months, with assessments at baseline, 3 months, and 6 months, and found that active treatment improved skin relief and silicone-replica topography and produced favorable changes on end-of-study immunohistochemistry and electron microscopy of dermal biopsies — biopsy-level evidence of structural remodeling, not merely surface appearance. A review by Farris published in Dermatologic Surgery in 2005 synthesized the photoaging evidence and established the evidence framework for topical vitamin C that remains in use today, noting that the evidence for topical vitamin C in photoaging is substantial relative to most cosmetic actives. Murray and colleagues published work in the Journal of the American Academy of Dermatology in 2008 showing that topical vitamin C combined with vitamin E and ferulic acid protects human skin from UV-induced thymine dimer mutations — quantitative photoprotection at the DNA level.

As with glutathione, the route-of-administration question applies to ascorbic acid in an injectable blend. The robust evidence base described above applies to topical and dietary delivery. Whether systemic injection delivers ascorbic acid to the dermis in concentrations that meaningfully exceed what the body achieves through normal dietary intake has not been established in controlled skin-outcome studies. Ascorbic acid does participate in tissue repair systemically, but the dose-response relationship at the skin level for an injectable cosmetic preparation is not characterized by published RCT data.

What the Blend Has and Has Not Been Studied For

What individual ingredient research supports

Taking each ingredient at face value and accounting for its best-characterized delivery route, the following is consistent with the published evidence: GHK-Cu modulates collagen gene expression and dermal tissue remodeling in preclinical and ex vivo models; glutathione attenuates melanin synthesis through tyrosinase and intracellular trafficking effects, with modest clinical evidence for skin-lightening at oral doses; and ascorbic acid supports collagen synthesis as a required enzymatic cofactor, with strong topical and dietary evidence for photoaging outcomes. These are real biological mechanisms supported by peer-reviewed literature.

What the blend itself has not been studied for

No randomized controlled trial has been published evaluating the GHK-Cu + glutathione + ascorbic acid combination as an injectable preparation for any skin outcome. The evidence discussed above comes from individual ingredient studies using topical, oral, in vitro, or ex vivo delivery systems — not the injectable blend as it is dispensed by compounding pharmacies. Extrapolating from topical GHK-Cu or oral glutathione data to a subcutaneous or intramuscular injection of a combined formula is a significant inferential step that the existing literature does not support directly. Formulation, dosing, bioavailability kinetics, and interaction effects between the three ingredients in an injectable matrix have not been characterized in published clinical research.

The intravenous safety signal

A 2025 case report by Johnson and Jarvis published in the Journal of Burn Care and Research documented a case of Stevens-Johnson syndrome and toxic epidermal necrolysis attributed to intravenous glutathione combined with vitamin C and vitamin D infusions. Stevens-Johnson syndrome is a rare but life-threatening mucocutaneous reaction. This is a single case report, not epidemiological data, but it illustrates that injectable cosmetic infusion blends containing glutathione and ascorbic acid carry a real adverse event profile that warrants provider supervision. IV glutathione specifically has been flagged in the systematic review literature as contraindicated; this case extends that concern to combined infusion preparations. The safety context for compounded injectable preparations generally is informed by a 2018 review in the Journal of Patient Safety by Shehab, Brown, and colleagues at the CDC, which documented that U.S. compounding pharmacy-related outbreaks between 2001 and 2013 included serious infection events traced to sterile injectable preparations, emphasizing that compounding quality and sterility are not equivalent to FDA-manufactured drug standards.

How GLOW Differs from Other Skin Peptides

GHK-Cu versus Argireline and Matrixyl

Argireline (acetyl hexapeptide-3) and Matrixyl (palmitoyl pentapeptide-4) are the most frequently cited cosmetic peptide alternatives. Both are topical compounds. Argireline functions as a localized neuromodulator by inhibiting the SNARE complex involved in neurotransmitter release, with proposed effects on expression lines; its mechanism is fundamentally different from GHK-Cu's tissue-remodeling activity. Matrixyl stimulates collagen and fibronectin synthesis through TGF-beta pathway activation. Neither has been studied in injectable formulations. GHK-Cu has a longer and more extensive research history than either alternative, and its gene-expression breadth across tissue-remodeling pathways is better characterized. The choice between these compounds is formulation- and delivery-dependent; none has RCT evidence in injectable cosmetic use.

Injectable GLOW versus topical GHK-Cu products

Topical GHK-Cu products are widely available and have a documented safety record spanning decades of over-the-counter cosmetic use. Injectable GLOW is a prescription-only compounded preparation with substantially higher systemic exposure, a sterility requirement, an injection-site reaction risk, and the additional complexity of glutathione and ascorbic acid co-administration. The 2025 BioImpacts review noted that the translational barrier for topical GHK-Cu is poor skin penetration, which is precisely what injectable delivery is designed to address — but this does not mean injectable delivery has equivalent efficacy data. It means the penetration barrier is circumvented; whether the resulting tissue-level effects match what the topical mechanistic data predicts has not been formally tested.

GLOW versus glutathione-only IV drip

IV glutathione infusions for skin lightening are marketed widely but have been specifically flagged in peer-reviewed literature as contraindicated for lack of efficacy evidence and adverse side-effect profile. A 2025 systematic review by Sarkar, Yadav, and colleagues in the International Journal of Dermatology characterized glutathione as moderately effective for topical and oral use while explicitly noting that intravenous glutathione is contraindicated due to lack of efficacy and adverse side effects. The GLOW blend differs in that glutathione is typically delivered subcutaneously or intramuscularly in lower doses, not intravenously, and is combined with GHK-Cu and ascorbic acid rather than given alone. This does not exempt it from the systemic safety considerations that apply to IV glutathione, but the route and dose context are meaningfully different. The IV glutathione contraindication applies specifically to the intravenous, high-dose route and should not be conflated with all injectable forms.

Regulatory Landscape

As of April 2026, no formulation of GHK-Cu, glutathione, or ascorbic acid has FDA approval as an injectable preparation for skin rejuvenation or pigmentation reduction. GHK-Cu is not FDA-approved for any human indication. Glutathione is available as an FDA-approved inhalation solution for AIDS-related pneumocystis pneumonia prophylaxis (under specific trade names), but not for cosmetic or skin-lightening use. Ascorbic acid is FDA-approved as an intravenous vitamin C preparation for specific nutritional deficiency states, not for cosmetic skin applications.

The GLOW blend is dispensed under Section 503A of the Federal Food, Drug, and Cosmetic Act, which governs traditional compounding pharmacies preparing patient-specific prescriptions. Under 503A, a licensed pharmacy may compound a preparation from approved bulk ingredients with a valid prescription, even if the resulting compound lacks its own FDA approval. This is the legal framework under which GLOW preparations are dispensed. 503A compounding is subject to state pharmacy board oversight and USP sterility standards for injectable preparations, but it is not subject to the FDA's drug approval process, pre-market review, or post-market surveillance requirements that apply to branded pharmaceutical products.

As of April 2026, GHK-Cu, glutathione, and ascorbic acid do not appear on the FDA's list of bulk drug substances that may not be used in compounding (the 503A "negative list"). However, the regulatory landscape for compounded preparations is actively evolving, and prescribers and patients should consult current FDA guidance and state pharmacy regulations, which may change. All injectable compounded preparations require a prescription from a licensed healthcare provider.

Safety and Side Effects

Because no RCT has been published for the injectable GLOW blend specifically, its adverse-event profile cannot be characterized with the statistical precision available for FDA-approved drugs. The following reflects the known safety considerations for its individual components and for injectable compounded preparations generally.

• Injection-site reactions: Subcutaneous and intramuscular injections carry inherent risks of local pain, erythema, bruising, and infection at the injection site. These are common with any injectable preparation and are managed through proper injection technique and sterile preparation.
• Compounding sterility: Compounded sterile preparations are associated with a documented risk of contamination-related infections when pharmacy sterility standards are not met. This is not a risk specific to GLOW but applies to all compounded injectables.
• Ascorbic acid dose-dependent effects: At high systemic doses, ascorbic acid can cause osmotic diarrhea, renal oxalate stone formation, and in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, hemolytic anemia. The systemic dose delivered by an injectable GLOW preparation depends on the compounded concentration and volume, which varies by pharmacy.
• Glutathione adverse effects and contraindications: The 2025 systematic review by Sarkar and Yadav explicitly noted that intravenous glutathione is contraindicated due to lack of efficacy evidence and adverse side effects. The case report by Johnson and Jarvis documented a severe cutaneous adverse reaction to an IV preparation combining glutathione and ascorbic acid. The subcutaneous or intramuscular route used in most GLOW protocols differs from IV delivery in pharmacokinetic profile, but the safety signals warrant provider supervision and informed patient consent.
• Copper accumulation (GHK-Cu): GHK-Cu delivers copper as part of its active complex. Copper is an essential trace element; however, accumulation with chronic injectable use has not been characterized in long-term published studies. Individuals with Wilson's disease or copper metabolism disorders should not receive copper-containing injectable preparations.
• Long-term safety: As of April 2026, no long-term safety data exist for the injectable GLOW blend. Duration, frequency, and cumulative dose effects are not characterized in the published literature.

Who May Be Evaluated for This Type of Preparation

A licensed provider determines whether a compounded injectable preparation is appropriate for a given patient. Because GLOW is a cosmetic rather than disease-directed preparation, evaluation criteria are less standardized than for FDA-approved therapeutics. Providers generally assess: overall health status and absence of contraindications (including Wilson's disease, G6PD deficiency, active renal disease, and pregnancy); informed understanding of the evidence limitations; and the absence of conditions that would make injectable delivery higher-risk. Individuals who have experienced hypersensitivity reactions to any of the ingredient classes, who are immunocompromised, or who are pregnant or breastfeeding are generally not candidates. The cosmetic application context does not reduce the need for clinical oversight of an injectable preparation.

What to Test Before Starting

Because GLOW contains pharmacologically active compounds delivered systemically, baseline laboratory assessment is clinically appropriate before initiating any injectable cosmetic preparation. The following markers are relevant to safety clearance and baseline establishment.

• Liver enzymes (ALT, AST, GGT). Baseline liver function is standard safety screening before any systemic preparation. GHK-Cu was originally characterized for its liver-protective effects, and glutathione metabolism runs through the liver — both reasons to know where hepatic biomarkers stand before introducing either compound. See the GGT biomarker guide for reference ranges and interpretation.
• Renal function (creatinine, eGFR). Ascorbic acid at systemic doses increases urinary oxalate excretion, and compromised renal function contraindicates high-dose IV ascorbic acid and warrants caution with injectable forms. The eGFR guide covers how filtration thresholds are interpreted clinically.
• CBC (complete blood count). Serves as a general safety baseline. G6PD-deficient individuals face hemolytic anemia risk from ascorbic acid; while G6PD status is not measured by a standard CBC, abnormal RBC morphology can surface when hemolysis is active and is worth tracking in context.
• hs-CRP. GHK-Cu is proposed to modulate inflammatory gene expression, so establishing a baseline inflammatory marker is appropriate before any intervention and particularly relevant when the preparation is being considered for inflammatory skin conditions.
• Serum copper and ceruloplasmin. GHK-Cu introduces exogenous copper systemically. Baseline copper stores and ceruloplasmin determine whether additional copper exposure is physiologically appropriate and help rule out undiagnosed copper metabolism disorders before treatment begins.
• Serum vitamin C. Baseline ascorbic acid status determines whether supplemental ascorbic acid is physiologically warranted and prevents high-dose delivery to individuals who are already replete.

Understanding Your Baseline

The principle behind baseline testing is direct: measure first, then decide. Every injectable preparation introduces compounds into the body systemically, and knowing where key safety biomarkers stand before the first injection makes it possible to detect any relevant changes with subsequent monitoring. For GLOW specifically, liver function, renal function, copper status, and inflammatory markers are the clinically relevant starting points. That approach — grounding clinical decisions in what objective data shows — is central to Superpower's approach to preventive health.

IMPORTANT SAFETY INFORMATION

GLOW (Klow) and similar branded injectable skin peptide blends are compounded preparations that are NOT FDA-approved for any indication. They are not manufactured under FDA drug manufacturing standards. The active ingredients — GHK-Cu (copper tripeptide-1), glutathione, and ascorbic acid — have not been evaluated as a combined injectable preparation in published clinical trials reviewed by the FDA for safety or efficacy. Formulations, concentrations, and excipients vary by compounding pharmacy and are not standardized. Superpower is a technology platform; Superpower does not prescribe or dispense medications.

These preparations may only be dispensed upon a licensed prescriber's patient-specific determination that a compounded preparation is clinically appropriate. This educational content does not constitute a clinical evaluation and cannot be used as the basis for a prescription.

Contraindications and conditions warranting additional clinical evaluation: Wilson's disease or other copper metabolism disorders (GHK-Cu); glucose-6-phosphate dehydrogenase (G6PD) deficiency (ascorbic acid); active renal disease or nephrolithiasis (ascorbic acid); known hypersensitivity to any ingredient class; pregnancy or breastfeeding; immunocompromised status.

Warnings: Injectable glutathione — particularly intravenous delivery — has been noted as contraindicated in systematic review literature due to insufficient evidence of efficacy and adverse side-effect profile, per a 2025 systematic review by Sarkar, Yadav, and colleagues in the International Journal of Dermatology. A case of Stevens-Johnson syndrome and toxic epidermal necrolysis has been reported following intravenous infusion of glutathione combined with vitamin C in a 2025 case report by Johnson, Jarvis, and colleagues in the Journal of Burn Care and Research. Compounded sterile preparations carry a documented risk of contamination-related infection when pharmacy sterility standards are not maintained. High-dose systemic ascorbic acid may cause renal oxalate stones and hemolytic anemia in susceptible individuals. Long-term safety data for the combined injectable blend do not exist as of April 2026.

Common adverse effects (based on individual ingredient data and compounded injectable preparations generally): injection-site pain, erythema, bruising; gastrointestinal discomfort; headache. Hypersensitivity reactions have been reported with injectable preparations in this class.

As of April 2026, GHK-Cu, glutathione, and ascorbic acid are not on the FDA 503A bulk drug substance "negative list," meaning they may legally be compounded under 503A. This status may change as FDA review of bulk substances continues. Prescribers and patients should verify current regulatory status before initiating or continuing any compounded preparation.

Full prescribing information for FDA-approved ascorbic acid injection products is available at dailymed.nlm.nih.gov. No FDA-approved prescribing information exists for the GLOW blend formulation.

Additional Questions

Are there clinical trials for the GLOW or Klow blend?

As of April 2026, no published randomized controlled trial has evaluated the injectable GHK-Cu + glutathione + ascorbic acid combination for any skin outcome. Evidence exists for individual ingredients through separate clinical and preclinical studies, but the blend as a combined injectable preparation has not been formally evaluated in a controlled trial. Research suggests meaningful mechanisms for each ingredient; it does not confirm clinical efficacy for the combined injectable form.

Is GLOW peptide FDA-approved?

No. The GLOW blend is not FDA-approved for any indication. Each ingredient has regulatory status in other contexts — ascorbic acid for nutritional deficiency, glutathione for a specific inhalation indication — but the combination as an injectable cosmetic does not have FDA approval. It is dispensed as a compounded preparation under Section 503A of the Federal Food, Drug, and Cosmetic Act.

What are the risks of injectable cosmetic blends like GLOW?

Known risk considerations include: injection-site reactions; compounding pharmacy sterility failures (documented in published outbreak data); ascorbic acid toxicity at high doses in G6PD-deficient individuals; the specific contraindication for intravenous glutathione noted in systematic reviews; a published case report of severe cutaneous adverse reaction to an IV preparation combining glutathione and ascorbic acid; and unknown long-term safety given the absence of longitudinal data. Provider supervision and baseline testing are appropriate before starting any injectable compounded preparation.

Do I need a prescription for GLOW peptide?

Yes. GLOW and similar branded compounded injectable blends are prescription-only preparations. They require a patient-specific prescription from a licensed healthcare provider and are dispensed exclusively by licensed 503A compounding pharmacies. They are not available over the counter or without a clinical evaluation.

What blood tests should I have before starting injectable skin peptides?

Clinically relevant baseline markers before an injectable cosmetic preparation include liver enzymes (ALT, AST, GGT), renal function (creatinine, eGFR), a complete blood count, baseline hs-CRP for inflammatory context, serum copper and ceruloplasmin to assess copper status before GHK-Cu delivery, and serum vitamin C to establish ascorbic acid baseline. A provider will determine the appropriate scope of testing based on individual health history.

Q11: How does GLOW compare to topical GHK-Cu products? A11:

Topical GHK-Cu products have a decades-long safety record in over-the-counter cosmetics. The primary limitation of topical delivery is poor skin penetration, which limits the compound's ability to reach the dermis. Injectable delivery addresses the penetration barrier but introduces systemic exposure, sterility requirements, and the additional complexity of co-administered glutathione and ascorbic acid. The clinical outcomes for injectable versus topical delivery have not been compared in a controlled trial. Topical forms are lower-risk; injectable forms require prescription and clinical oversight.